Q-omics provides the consensus-scored EFCAB8 profile across patient tissues and cancer cell-line models. EFCAB8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EFCAB8 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, EFCAB8 RNA expression shows 14,807 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where EFCAB8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EFCAB8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EFCAB8 survival associations across molecular data types. EFCAB8 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EFCAB8 RNA expression–survival associations across cancer types. High EFCAB8 expression shows unfavorable associations in KIRC, UVM, LUSC, ACC and LGG, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EFCAB8 RNA expression.
This table summarizes EFCAB8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EFCAB8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EFCAB8 shows higher tumor expression in KIRC, LIHC, UCEC, HNSC, COAD and LUSC. The KIRC box plot shows higher EFCAB8 RNA expression in tumor versus normal tissue (log2 FC = +0.026, t-test p < 0.001).
This table shows molecular features associated with EFCAB8 in patient tissues and cancer cell lines. In patient samples, EFCAB8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, EFCAB8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BREAST.
